Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caris Life Sciences (CAI) Non-Current Assets (2024 - 2025)

Caris Life Sciences has reported Non-Current Assets over the past 2 years, most recently at $127.9 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $127.9 million for Q4 2025, changed 0.11% from a year ago — trailing twelve months through Dec 2025 was $507.9 million (changed N/A YoY), and the annual figure for FY2025 was $127.9 million, changed 0.11%.
  • Non-Current Assets for Q4 2025 was $127.9 million at Caris Life Sciences, down from $130.3 million in the prior quarter.
  • Over the last five years, Non-Current Assets for CAI hit a ceiling of $130.3 million in Q3 2025 and a floor of $121.7 million in Q2 2025.